The invention relates to the compound (S)-n-hydroxy-2-(2-(4-methoxyphenyl) butanamido)thiazole-5-carboxamide, which is a novel histone deacetylase inhibitor. The invention further relates to the use of the compound for the inhibition of histone deacetylating activities of HDAC isoforms and treatment of histone deacetylase (HDAC)-associated diseases. The invention also relates to the pharmaceutical compositions and the making of the pharmaceutical compositions comprising the compound.

Modified ribosomes that were selected using a dipeptidyl-puromycin aminonucleoside are used to mediate site-specific incorporation of one or more peptides and peptidomimetics into protein in a cell free translation system. In addition, new fluorescent dipeptidomimetics have been synthesized and incorporated into proteins, as well as modified proteins containing one or more non-naturally occurring dipeptides.

Modified ribosomes that were selected using a dipeptidyl-puromycin aminonucleoside are used to mediate site-specific incorporation of one or more peptides and peptidomimetics into protein in a cell free translation system. In addition, new fluorescent dipeptidomimetics have been synthesized and incorporated into proteins, as well as modified proteins containing one or more non-naturally occurring dipeptides.

The invention relates to the compound (S)-n-hydroxy-2-(2-(4-methoxyphenyl) butanamido)thiazole-5-carboxamide, which is a novel histone deacetylase inhibitor. The invention further relates to the use of the compound for the inhibition of histone deacetylating activities of HDAC isoforms and treatment of histone deacetylase (HDAC)-associated diseases. The invention also relates to the pharmaceutical compositions and the making of the pharmaceutical compositions comprising the compound.

The invention relates to the compound (S)-n-hydroxy-2-(2-(4-methoxyphenyl) butanamido)thiazole-5-carboxamide, which is a novel histone deacetylase inhibitor. The invention further relates to the use of the compound for the inhibition of histone deacetylating activities of HDAC isoforms and treatment of histone deacetylase (HDAC)-associated diseases. The invention also relates to the pharmaceutical compositions and the making of the pharmaceutical compositions comprising the compound.

Scaffold compounds are used to design small molecule compounds and structure-activity relationship studies identify inhibitors of inflammation. Methods include pharmaceutical compositions of the small molecule compounds to inhibit, prevent and treat diseases and conditions associated with inflammation, including multiple sclerosis, Alzheimer's disease, acute myocardial infarction, traumatic brain injury and autoinflammatory diseases.

Scaffold compounds are used to design small molecule compounds and structure-activity relationship studies identify inhibitors of inflammation. Methods include pharmaceutical compositions of the small molecule compounds to inhibit, prevent and treat diseases and conditions associated with inflammation, including multiple sclerosis, Alzheimer's disease, acute myocardial infarction, traumatic brain injury and autoinflammatory diseases.

In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided.

In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided.

In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided.